| Year |
Citation |
Score |
| 2023 |
Jeon HY, Pornour M, Ryu H, Khadka S, Xu R, Jang J, Li D, Chen H, Hussain A, Fazli L, Gleave M, Dong X, Huang F, Wang Q, Barbieri C, et al. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research. PMID 36727462 DOI: 10.1093/nar/gkad043 |
0.389 |
|
| 2022 |
Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang NJ, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. European Urology. PMID 36243543 DOI: 10.1016/j.eururo.2022.09.010 |
0.353 |
|
| 2022 |
Adediran S, Wang L, Khan MA, Guang W, Fan X, Dan H, Qi J, Jay SM, Carrier F, Hussain A. Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. Cancers. 14. PMID 36230550 DOI: 10.3390/cancers14194626 |
0.306 |
|
| 2022 |
Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. Bmc Cancer. 22: 304. PMID 35317768 DOI: 10.1186/s12885-022-09364-z |
0.404 |
|
| 2022 |
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, ... ... Hussain A, et al. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 35142815 DOI: 10.1001/jamaoncol.2021.7298 |
0.425 |
|
| 2021 |
Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, et al. Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34598946 DOI: 10.1158/1078-0432.CCR-21-2199 |
0.367 |
|
| 2021 |
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, et al. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002759. PMID 33617303 DOI: 10.1200/JCO.20.02759 |
0.419 |
|
| 2020 |
Barry KH, Mohanty K, Erickson PA, Wang D, Shi J, Rose G, Cellini A, Clark K, Ambulos N, Yin J, Yan L, Poulin M, Meyer A, Zhang Y, Bentzen SM, ... ... Hussain A, et al. DNA Methylation in Prostate Tumor Tissue Is Associated with Gleason Score. Genes. 12. PMID 33374332 DOI: 10.3390/genes12010012 |
0.353 |
|
| 2020 |
Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33028943 DOI: 10.1038/s41391-020-00296-y |
0.403 |
|
| 2020 |
Xu S, Fan L, Jeon HY, Zhang F, Cui X, Mickle MB, Peng G, Hussain A, Fazli L, Gleave ME, Dong X, Qi J. p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer. Cancer Research. PMID 32522824 DOI: 10.1158/0008-5472.Can-20-0233 |
0.532 |
|
| 2020 |
Fan L, Xu S, Zhang F, Cui X, Fazli L, Gleave M, Clark DJ, Yang A, Hussain A, Rassool F, Qi J. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death & Disease. 11: 214. PMID 32238799 DOI: 10.1038/S41419-020-2405-4 |
0.463 |
|
| 2020 |
Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases. PMID 32111923 DOI: 10.1038/S41391-020-0213-7 |
0.473 |
|
| 2020 |
Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Heath EI, Tutrone RF, Schellhammer PF, et al. Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-D084 |
0.477 |
|
| 2019 |
Passaniti A, Hussain A. Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes. Annals of Translational Medicine. 7: S335. PMID 32016053 DOI: 10.21037/Atm.2019.09.109 |
0.508 |
|
| 2019 |
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. The Prostate. PMID 31742767 DOI: 10.1002/Pros.23922 |
0.528 |
|
| 2019 |
Kwegyir-Afful AK, Ramalingam S, Ramamurthy VP, Purushottamachar P, Murigi FN, Vasaitis TS, Huang W, Kane MA, Zhang Y, Ambulos N, Tiwari S, Srivastava P, Nnane IP, Hussain A, Qiu Y, et al. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. Cancers. 11. PMID 31653008 DOI: 10.3390/Cancers11111637 |
0.455 |
|
| 2019 |
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, et al. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. The Oncologist. PMID 31152080 DOI: 10.1634/Theoncologist.2019-0331 |
0.481 |
|
| 2019 |
Schardt JS, Noonan-Shueh M, Oubaid JM, Pottash AE, Williams SC, Hussain A, Lapidus RG, Lipkowitz S, Jay SM. HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model. The Aaps Journal. 21: 48. PMID 30949858 DOI: 10.1208/S12248-019-0318-X |
0.383 |
|
| 2019 |
Kaiser A, Haskins C, Siddiqui MM, Hussain A, D'Adamo C. The evolving role of diet in prostate cancer risk and progression. Current Opinion in Oncology. PMID 30893147 DOI: 10.1097/CCO.0000000000000519 |
0.374 |
|
| 2019 |
Kaiser A, Eley JG, Onyeuku NE, Rice SR, Wright CC, McGovern NE, Sank M, Zhu M, Vujaskovic Z, Simone CB, Hussain A. Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies. Journal of Visualized Experiments : Jove. PMID 30799838 DOI: 10.3791/58372 |
0.378 |
|
| 2019 |
Rice SR, Olexa G, Hussain A, Mannuel H, Naslund MJ, Amin P, Kwok Y. A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer. American Journal of Clinical Oncology. PMID 30676332 DOI: 10.1097/Coc.0000000000000520 |
0.507 |
|
| 2019 |
Shah A, Hussain A, Shah R, Ikeme S, Mohamed AF, Botteman M, Waldeck R. Predictors and rates of adverse events (AEs) among non-metastatic prostate cancer (nmPC) patients (pts) treated with bicalutamide, abiraterone, or enzalutamide following surgical/medical castration. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16556 |
0.443 |
|
| 2019 |
Sartor AO, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, et al. Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. Journal of Clinical Oncology. 37: 5035-5035. DOI: 10.1200/Jco.2019.37.15_Suppl.5035 |
0.516 |
|
| 2019 |
Abida W, Bryce AH, Vogelzang NJ, Amato RJ, Percent IJ, Shapiro JD, McDermott RS, Hussain A, Patnaik A, Petrylak DP, Ryan CJ, Stanton TS, Zhang J, Loehr A, Simmons A, et al. Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. Journal of Clinical Oncology. 37: 5031-5031. DOI: 10.1200/Jco.2019.37.15_Suppl.5031 |
0.471 |
|
| 2019 |
Barry KH, Mohanty K, Rose G, Cellini A, Ambulos N, Yin J, Yan L, Poulin M, Meyer A, Zhang Y, Bentzen S, Burke A, Hussain A, Berndt SI. Abstract 611: MYC DNA methylation in prostate tumor tissue is associated with tumor aggressiveness Cancer Research. 79: 611-611. DOI: 10.1158/1538-7445.Sabcs18-611 |
0.473 |
|
| 2019 |
Xu S, Fan L, Cui X, Zhang F, Hussain A, Fazli L, Gleave M, Qi J. Abstract 4389: Post-translational modifications of histone demethylase JMJD1A in prostate cancer cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4389 |
0.484 |
|
| 2019 |
Grivas P, Teo MY, Vogelzang N, Alva A, Zakharia Y, Adra N, Drakaki A, Hussain A, Morales-Barrera R, Necchi A, Rodriguez-Vida A, Feyerabend S, Gupta S, Josephs DH, Loriot Y, et al. Abstract CT179: ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct179 |
0.412 |
|
| 2019 |
Taplin M, Hussain A, Shah S, Shore ND, Edenfield WJ, Sartor OA, Nordquist LT, Agrawal M, Clark W, Wise DR, Oh WK, Fleming MT, Butrynski JE, Chatta GS, Bupathi M, et al. Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct094 |
0.425 |
|
| 2019 |
Green F, Shapiro JD, McDermott R, Piulats JM, Reid A, Ostler P, Zhang J, Campbell D, Spaeth D, Percent I, Hussain A, Simmons AD, Golsorkhi T, Watkins SP, Loehr A, et al. Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies Cancer Research. 79: 727-727. DOI: 10.1158/1538-7445.Am2019-727 |
0.364 |
|
| 2019 |
Piulats JM, Abida W, McDermott R, Shapiro JD, Ostler P, Reaume MN, Mejlholm I, Byard I, Hussain A, Morris D, Campbell D, Burke J, Laguerre B, Reid A, Voog E, et al. Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA) European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30351-3 |
0.467 |
|
| 2019 |
Shah A, Hussain A, Shah R, Ikeme S, Mohamed A, Waldeck R, Botteman M. Pcn137 Economic Burden Associated With Adverse Events Among Patients With Non-Metastatic Prostate Cancer Treated With Bicalutamide, Enzalutamide Or Abiraterone Following Androgen Deprivation Therapy (Surgical/Medical Castration) Value in Health. 22. DOI: 10.1016/J.Jval.2019.04.261 |
0.494 |
|
| 2018 |
Chowdhury S, McDermott R, Piulats JM, Shapiro JD, Mejlholm I, Morris D, Ostler P, Hussain A, Dumbadze I, Goldfischer ER, Pintus E, Benjelloun A, Gross ME, Tejwani S, Chatta G, et al. Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii273. PMID 32136628 DOI: 10.1093/Annonc/Mdy284.004 |
0.459 |
|
| 2018 |
Onukwugha E, Albarmawi H, Sun K, Mullins CD, Aly A, Hussain A. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis. Urologic Oncology. PMID 29724482 DOI: 10.1016/J.Urolonc.2018.03.023 |
0.506 |
|
| 2018 |
Fan L, Zhang F, Xu S, Cui X, Hussain A, Fazli L, Gleave M, Dong X, Qi J. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 29712835 DOI: 10.1073/Pnas.1802415115 |
0.477 |
|
| 2018 |
Kujtan L, Hussain A, Subramanian J, Masood A. The evolving genomic landscape in urothelial cancer. Current Opinion in Oncology. PMID 29538042 DOI: 10.1097/Cco.0000000000000447 |
0.321 |
|
| 2018 |
Taplin M, Hussain A, Shore ND, Bradley B, Trojer P, Lebedinsky C, Senderowicz AM, Antonarakis ES. A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps398 |
0.541 |
|
| 2018 |
Abida W, Bryce AH, Balar AV, Chatta GS, Dawson NA, Guancial EA, Hussain A, Jha GG, Lipsitz DU, Patnaik A, Petrylak DP, Ryan CJ, Stanton TS, Vogelzang NJ, Zhang J, et al. TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps388 |
0.423 |
|
| 2018 |
Abida W, Bryce AH, Vogelzang NJ, Amato RJ, Percent I, Shapiro JD, McDermott R, Hussain A, Patnaik A, Petrylak D, Ryan CJ, Stanton T, Zhang J, Simmons AD, Despain D, et al. Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.002 |
0.486 |
|
| 2017 |
Onukwugha E, Kwok Y, Ciezki JP, Yong C, Plaisant C, Reddy CA, Mullins CD, Seal B, Valderrama A, Hussain A. Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone. Plos One. 12: e0175956. PMID 28419139 DOI: 10.1371/Journal.Pone.0175956 |
0.375 |
|
| 2017 |
Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, Hussain A, Njar VC. Targeting of protein translation as a new treatment paradigm for prostate cancer. Current Opinion in Oncology. PMID 28282343 DOI: 10.1097/Cco.0000000000000367 |
0.489 |
|
| 2017 |
Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Molecular Pharmaceutics. PMID 28248115 DOI: 10.1021/Acs.Molpharmaceut.6B00919 |
0.391 |
|
| 2017 |
Rice S, Le GK, Hussain A, Mannuel HD, Naslund MK, Amin PP, Kwok Y. Long-term results of a prospective phase II study of androgen deprivation therapy, external radiation, cs-131 brachytherapy, and adjuvant docetaxel in high-risk prostate cancer. Journal of Clinical Oncology. 35: 5079-5079. DOI: 10.1200/Jco.2017.35.15_Suppl.5079 |
0.408 |
|
| 2017 |
Fu D, Huang H, Song J, Xu M, Liu L, Khan MA, Chandrasekaran K, Hussain A, Sriram G, Siddiqui MM. Abstract 4414: Arginine metabolism is modulated by androgen signalling and prostate cancer progression Cancer Research. 77: 4414-4414. DOI: 10.1158/1538-7445.Am2017-4414 |
0.484 |
|
| 2017 |
Kwok Y, Le G, Rice SR, Mannuel H, Naslund M, Amin PP, Hussain A. A Phase 2 Study of Androgen Deprivation Therapy, Bone Marrow Sparing Pelvic IMRT, Cs-131 Brachytherapy Boost, and Adjuvant Docetaxel in High-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1202 |
0.477 |
|
| 2016 |
Onukwugha E, Yong C, Naslund M, Woods C, Mullins CD, Seal B, Hussain A. Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. Urologic Oncology. PMID 28041997 DOI: 10.1016/J.Urolonc.2016.11.012 |
0.509 |
|
| 2016 |
Hussain A, Aly A, Daniel Mullins C, Qian Y, Arellano J, Onukwugha E. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis. Cancer Medicine. PMID 27730756 DOI: 10.1002/Cam4.914 |
0.437 |
|
| 2016 |
Rutenberg MS, Meister M, Amin PP, Hussain A, Naslund MJ, Kwok Y. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy. Brachytherapy. PMID 27693225 DOI: 10.1016/J.Brachy.2016.08.004 |
0.517 |
|
| 2016 |
Zhang Y, Lapidus RG, Liu P, Choi EY, Adediran S, Hussain A, Wang X, Liu X, Dan HC. Targeting IκB kinase β/NF-κB signaling in human prostate cancer by a novel IκB kinase β inhibitor CmpdA. Molecular Cancer Therapeutics. PMID 27196761 DOI: 10.1158/1535-7163.Mct-15-0999 |
0.424 |
|
| 2016 |
McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27044933 DOI: 10.1200/Jco.2015.65.3154 |
0.515 |
|
| 2016 |
Twum-Ampofo J, Fu DX, Passaniti A, Hussain A, Siddiqui MM. Metabolic targets for potential prostate cancer therapeutics. Current Opinion in Oncology. PMID 26907571 DOI: 10.1097/Cco.0000000000000276 |
0.398 |
|
| 2016 |
Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, Stadler WM, Hammers HJ, Appleman LJ, Tsao C, Pal SK, Hussain A, Jim HS, Borham A, George DJ. Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry. Journal of Clinical Oncology. 34: e16097-e16097. DOI: 10.1200/Jco.2016.34.15_Suppl.E16097 |
0.307 |
|
| 2016 |
Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, Stadler WM, Hammers HJ, Appleman LJ, Tsao C, Pal SK, Hussain A, Jim HS, Borham A, George DJ. Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry. Journal of Clinical Oncology. 34: e16084-e16084. DOI: 10.1200/Jco.2016.34.15_Suppl.E16084 |
0.316 |
|
| 2016 |
Xie Y, Wang L, Hussain A. Abstract 272: Metformin enhances the anti-prostate cancer activity of abiraterone and enzalutamide Cancer Research. 76: 272-272. DOI: 10.1158/1538-7445.Am2016-272 |
0.488 |
|
| 2016 |
Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A, Rassool F, Qi J. Abstract 1981: Histone demethyalase JMJD1A promotes the DNA damage response of prostate cancer cells Cancer Research. 76: 1981-1981. DOI: 10.1158/1538-7445.Am2016-1981 |
0.428 |
|
| 2016 |
Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A, Rassool F, qi j. MP90-04 A ROLE FOR HISTONE DEMETHYALASE JMJD1A IN THE DNA DAMAGE RESPONSE OF PROSTATE CANCER CELLS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2548 |
0.421 |
|
| 2015 |
Gao Y, Gartenhaus RB, Lapidus RG, Hussain A, Zhang Y, Wang X, Dan HC. Differential IKK/NF-kappaB Activity is Mediated by TSC2 through mTORC1 in PTEN-null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells. Molecular Cancer Research : McR. PMID 26374334 DOI: 10.1158/1541-7786.Mcr-15-0213 |
0.328 |
|
| 2015 |
Aly A, Onukwugha E, Woods C, Mullins CD, Kwok Y, Qian Y, Arellano J, Balakumaran A, Hussain A. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. Bmc Medical Research Methodology. 15: 65. PMID 26286392 DOI: 10.1186/s12874-015-0047-5 |
0.316 |
|
| 2015 |
Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A, Qi J. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene. PMID 26279298 DOI: 10.1038/Onc.2015.309 |
0.437 |
|
| 2015 |
Fan L, Peng G, Hussain A, Fazli L, Guns E, Gleave M, Qi J. The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells. The Journal of Biological Chemistry. PMID 26160177 DOI: 10.1074/Jbc.M115.662155 |
0.53 |
|
| 2015 |
McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 121: 2603-11. PMID 25903013 DOI: 10.1002/Cncr.29398 |
0.492 |
|
| 2015 |
Jayasekera J, Onukwugha E, Bikov K, Hussain A. Racial variation in the clinical and economic burden of skeletal-related events among elderly men with stage IV metastatic prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 15: 471-85. PMID 25817559 DOI: 10.1586/14737167.2015.1024662 |
0.43 |
|
| 2015 |
Qi J, Fan L, Hussain A. Implications of ubiquitin ligases in castration-resistant prostate cancer. Current Opinion in Oncology. 27: 172-6. PMID 25811345 DOI: 10.1097/Cco.0000000000000178 |
0.499 |
|
| 2015 |
Aly A, Mullins CD, Hussain A. Understanding heterogeneity of treatment effect in prostate cancer. Current Opinion in Oncology. 27: 209-16. PMID 25689354 DOI: 10.1097/Cco.0000000000000172 |
0.486 |
|
| 2015 |
Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells. Biochimica Et Biophysica Acta. 1849: 317-27. PMID 25615818 DOI: 10.1016/J.Bbagrm.2015.01.003 |
0.341 |
|
| 2015 |
Petrylak DP, Vogelzang NJ, Chatta GS, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer BG, et al. A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz). Journal of Clinical Oncology. 33: 144-144. DOI: 10.1200/Jco.2015.33.7_Suppl.144 |
0.46 |
|
| 2015 |
Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A, Qi J. Abstract LB-075: The histone demethylase JMJD1A is essential to prostate cancer cells through regulation of c-Myc expression Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-075 |
0.475 |
|
| 2015 |
Yong C, Onukwugha E, Mullins C, Zuckerman I, Hussain A, Naslund M. Comorbidity Burden And Incremental Cost of Fractures In Medicare Men With Non-Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy Value in Health. 18: A159. DOI: 10.1016/J.Jval.2015.03.921 |
0.478 |
|
| 2015 |
Jayasekera J, Onukwugha E, Bikov K, Hussain A. Racial variation in the Clinical and Economic burden of Skeletal-related events among elderly Men with stage iv metastatic Prostate Cancer Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1476 |
0.502 |
|
| 2015 |
Aly A, Hussain A, Mullins CD. Heterogeneity of Treatment Effect of Androgen Deprivation Therapy In Patients With Incident Metastatic Prostate Cancer Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.1120 |
0.532 |
|
| 2015 |
Petrylak D, Vogelzang N, Chatta K, Fleming M, Smith D, Appleman L, Hussain A, Modiano M, Singh P, Tagawa S, Gore I, McClay E, Mega A, Sartor O, Somer B, et al. Mp82-09 Prostate Specific Membrane Antigen Antibody Drug Conjugate (Psma Adc) In Patients (Pts) With Progressive Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Following Abiraterone And/Or Enzalutamide (Abi/Enz): Results From A Phase 2 Study The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.528 |
0.503 |
|
| 2014 |
Taplin M, Chi KN, Chu F, Cochran J, Edenfield WJ, Eisenberger M, Emmenegger U, Heath EI, Hussain A, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, Sartor O, et al. 757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv257. PMID 28174829 DOI: 10.1093/Annonc/Mdu336.5 |
0.318 |
|
| 2014 |
Kwok Y, Yong C, Franey C, Mullins CD, Seal BS, Valderrama A, Hussain A. Skeletal-related events (SREs) and survival among elderly patients with stage IV prostate cancer (PCa) in SEER Medicare data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 249. PMID 28142728 DOI: 10.1200/Jco.2014.32.31_Suppl.249 |
0.375 |
|
| 2014 |
Gardner JF, Jayasekera J, Malik S, Hussain A, Mullins CD, Valderrama A, Seal BS, Kwok Y. An algorithm to identify delivery of palliative radiation therapy using health care claims data: A proof of concept application of data visualization tools in the prostate cancer (PCa) setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 248. PMID 28142726 DOI: 10.1200/Jco.2014.32.31_Suppl.248 |
0.396 |
|
| 2014 |
Onukwugha E, Osteen P, Jayasekera J, Mullins CD, Mair CA, Hussain A. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors. Cancer. 120: 3385-92. PMID 24962590 DOI: 10.1002/Cncr.28894 |
0.488 |
|
| 2014 |
Yong C, Onukwugha E, Mullins CD, Seal B, Hussain A. The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis. Journal of Geriatric Oncology. 5: 290-8. PMID 24780283 DOI: 10.1016/J.Jgo.2014.04.001 |
0.317 |
|
| 2014 |
Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. Journal of Geriatric Oncology. 5: 281-9. PMID 24726866 DOI: 10.1016/J.Jgo.2014.03.002 |
0.425 |
|
| 2014 |
Kerr CL, Hussain A. Regulators of prostate cancer stem cells. Current Opinion in Oncology. 26: 328-33. PMID 24651383 DOI: 10.1097/Cco.0000000000000080 |
0.522 |
|
| 2014 |
Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1143-50. PMID 24590644 DOI: 10.1200/Jco.2013.51.6500 |
0.515 |
|
| 2014 |
Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 32: 173-91. PMID 24435407 DOI: 10.1007/S40273-013-0121-Y |
0.514 |
|
| 2014 |
Onukwugha E, Yong C, Hussain A, Seal B, Mullins CD. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. Bmc Medical Research Methodology. 14: 1. PMID 24383436 DOI: 10.1186/1471-2288-14-1 |
0.488 |
|
| 2014 |
Petrylak DP, Smith DC, Appleman LJ, Fleming MT, Hussain A, Dreicer R, Sartor AO, Shore ND, Vogelzang NJ, Youssoufian H, Olson WC, Stambler N, Huang K, Israel RJ. A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 83-83. DOI: 10.1200/Jco.2014.32.4_Suppl.83 |
0.516 |
|
| 2014 |
Yong C, Onukwugha E, Mullins CD, Abdulhalim AM, Qian Y, Arellano J, Balakumaran A, Liede A, Hussain A. Physician referral patterns among men with advanced prostate cancer. Journal of Clinical Oncology. 32: 211-211. DOI: 10.1200/Jco.2014.32.4_Suppl.211 |
0.409 |
|
| 2014 |
Abdulhalim AM, Onukwugha E, Woods C, Qian Y, Arellano J, Balakumaran A, Mullins CD, Hussain A. Prevalence of fractures among men with stage IV prostate cancer (S4PC). Journal of Clinical Oncology. 32: 143-143. DOI: 10.1200/Jco.2014.32.4_Suppl.143 |
0.368 |
|
| 2014 |
Hussain A, Abdulhalim AM, Mullins CD, Qian Y, Arellano J, Balakumaran A, Onukwugha E. Prevalence of first and subsequent skeletal-related events (SREs) in U.S. elderly patients with metastatic prostate cancer (mPC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16006 |
0.462 |
|
| 2014 |
Taplin M, Chi K, Chu F, Cochran J, Edenfield W, Antonarakis E, Emmenegger U, Heath E, Hussain A, Njar V, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, et al. 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 European Journal of Cancer. 50: 8. DOI: 10.1016/S0959-8049(14)70130-3 |
0.485 |
|
| 2014 |
Yong C, Onukwugha E, Mullins C, Zuckerman I, Hussain A, Naslund M. Use of Bone-Modifying Agents Following Androgen Deprivation Therapy for Medicare Non-Metastatic Prostate Cancer Patients Value in Health. 17: A99. DOI: 10.1016/J.Jval.2014.03.574 |
0.499 |
|
| 2014 |
Abdulhalim AM, Hussain A, Mullins CD, Qian Y, Arellano J, Balakumaran A, Onukwugha E. Burden and Timing of First and Subsequent Skeletal Related Events (SRES) in United States Elderly Men with Metastatic Prostate Cancer (MPC) Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.419 |
0.49 |
|
| 2014 |
Yong C, Onukwugha E, Mullins CD, Zuckerman I, Hussain A, Naslund M. MP78-04 ORAL AND INTRAVENOUS BISPHOSPHONATE USE FOLLOWING ANDROGEN DEPRIVATION THERAPY AMONG MEDICARE BENEFICIARIES WITH NON-METASTATIC PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2487 |
0.402 |
|
| 2014 |
Abdulhalim AM, Onukwugha E, Woods C, Qian Y, Arellano J, Balakumaran A, Mullins CD, Hussain A. Mp78-02 Cumulative Incidence Of Skeletal Related Events In Men With Metastatic Prostate Cancer Based On Alternative Algorithms The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2485 |
0.485 |
|
| 2014 |
Petrylak D, Smith DC, Appleman LJ, Fleming M, Hussain A, Dreicer R, Sartor AO, Shore N, Vogelzang NJ, Youssoufian H, Olson W, Stambler N, Huang K, Israel R. Mp70-20 A Phase 2 Trial Of Prostate Specific Membrane Antigen Antibody Drug Conjugate (Psma Adc) In Taxane-Treated Metastatic Castration-Resistant Prostate Cancer (Mcrpc) The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2218 |
0.496 |
|
| 2014 |
Meister M, Rutenberg M, Amin P, Hussain A, Naslund M, Kwok Y. Clinical Experience of Full-Dose External Beam Radiation in Prostate Cancer Patients Failing Initial Treatment With Prostate Brachytherapy International Journal of Radiation Oncology*Biology*Physics. 90: S445. DOI: 10.1016/J.Ijrobp.2014.05.1396 |
0.497 |
|
| 2013 |
Mannuel HD, Liu G, Lara P, Monk JP, Flaig TW, Zurita AJ, Vaishampayan UN, Stella PJ, Smith DW, Dobson K, Hussain A, Al-Janadi A, Ivy SP, Heilbrun LK. Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 38. PMID 28136984 DOI: 10.1200/Jco.2013.31.6_Suppl.38 |
0.382 |
|
| 2013 |
Halabi S, Ryan CJ, Stadler WM, Hussain A, Vogelzang NJ, Hauke RJ, Sanford BL, Small EJ. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 27. PMID 28136956 DOI: 10.1200/Jco.2013.31.6_Suppl.27 |
0.512 |
|
| 2013 |
Islam R, Jacobson C, Ritter MA, Mullins CD, Nallu A, Hussain A. Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 240. PMID 28136816 DOI: 10.1200/Jco.2013.31.6_Suppl.240 |
0.369 |
|
| 2013 |
Islam R, Mullins CD, Hussain A, Jacobson C, Foth W, Ritter MA. The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 242. PMID 28136810 DOI: 10.1200/Jco.2013.31.6_Suppl.242 |
0.423 |
|
| 2013 |
Mitikiri ND, Reese ES, Hussain A, Onukwugha E, Pritchard D, Dubois R, Mullins CD. The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. Journal of Comparative Effectiveness Research. 2: 605-18. PMID 24236799 DOI: 10.2217/Cer.13.70 |
0.396 |
|
| 2013 |
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 72: 537-44. PMID 23820963 DOI: 10.1007/S00280-013-2224-8 |
0.446 |
|
| 2013 |
Davidoff AJ, Zuckerman IH, Pandya N, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Weiner JP, Edelman MJ. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. Journal of Geriatric Oncology. 4: 157-65. PMID 23795223 DOI: 10.1016/J.Jgo.2012.12.005 |
0.324 |
|
| 2013 |
Nallu A, Mitikiri ND, Onukwugha E, Mullins CD, Hussain A. Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. Journal of Clinical Oncology. 31: 210-210. DOI: 10.1200/Jco.2013.31.6_Suppl.210 |
0.388 |
|
| 2013 |
Yong C, Onukwugha E, Mullins CD, Seal BS, Hussain A. Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). Journal of Clinical Oncology. 31: 203-203. DOI: 10.1200/Jco.2013.31.6_Suppl.203 |
0.313 |
|
| 2013 |
Mitikiri ND, Nallu A, Mullins CD, Onukwugha E, Hussain A. Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. Journal of Clinical Oncology. 31: 177-177. DOI: 10.1200/Jco.2013.31.6_Suppl.177 |
0.412 |
|
| 2013 |
Onukwugha E, Yong C, Mullins CD, Seal BS, Hussain A. Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). Journal of Clinical Oncology. 31: 133-133. DOI: 10.1200/Jco.2013.31.6_Suppl.133 |
0.405 |
|
| 2013 |
Jayasekera J, Onukwugha E, Bikov KA, Mullins CD, Seal BS, Hussain A. Incremental cost (IC) analysis of skeletal related events (SREs) among elderly men with stage IV metastatic (M1) prostate cancer (PCa). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E16034 |
0.411 |
|
| 2013 |
Onukwugha E, Yong C, Mullins CD, Seal BS, Hussain A. Skeletal-related events (SREs), baseline comorbidity, and survival among elderly patients (pts) with metastatic (M1) prostate cancer (PCa) in SEER-Medicare. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E16027 |
0.455 |
|
| 2013 |
Jayasekera J, Onukwugha E, Mullins CD, Seal B, Bikov K, Hussain A. Cost Analysis Of Skeletal Related Events Among Elderly Men With Stage Iv Metastatic Prostate Cancer In Seer-Medicare Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.663 |
0.493 |
|
| 2013 |
Onukwugha E, Yong C, Mullins C, Seal B, Hussain A. Skeletal-Related Events And Mortality Among Seer-Medicare Patients With Metastatic Prostate Cancer: The Implications Of Measurement Approach Value in Health. 16. DOI: 10.1016/J.Jval.2013.03.060 |
0.485 |
|
| 2013 |
Yong C, Onukwugha E, Mullins CD, Seal B, Hussain A. 780 Differences In Provider Encounters Between Metastatic (M1) And Non-Metastatic (M0) Prostate Cancer (Pca) Patients The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.344 |
0.467 |
|
| 2013 |
Onukwugha E, Kwok Y, Yong C, Mullins C, Seal B, Hussain A. Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.919 |
0.394 |
|
| 2012 |
Zhang B, Suer S, Livak F, Adediran S, Vemula A, Khan MA, Ning Y, Hussain A. Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Molecular Pharmacology. 82: 310-21. PMID 22584221 DOI: 10.1124/Mol.111.076752 |
0.482 |
|
| 2012 |
Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S. Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer Journal of Clinical Oncology. 30: 661-666. PMID 22253467 DOI: 10.1200/Jco.2011.35.5198 |
0.304 |
|
| 2012 |
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 118: 4139-47. PMID 22180287 DOI: 10.1002/Cncr.26732 |
0.517 |
|
| 2012 |
Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Engstrom C, Dawson N, Amin P, Kwok Y. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy. International Journal of Radiation Oncology, Biology, Physics. 82: 167-74. PMID 21036487 DOI: 10.1016/J.Ijrobp.2010.09.009 |
0.51 |
|
| 2012 |
Onukwugha E, Mullins CD, Yong C, McNally DL, Seal BS, Hussain A. Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15148 |
0.468 |
|
| 2012 |
Hussain A, Onukwugha E, Jayasekera J, McNally DL, Seal BS, Mullins CD. Characteristics of stage III and IV M0 prostate cancer (PCa) patients in SEER-Medicare who develop bone metastasis (BM) following diagnosis. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15146 |
0.483 |
|
| 2012 |
Mitikiri ND, Reese ES, Hussain A, Onukwugha E, Pritchard D, Dubois RW, Mullins CD. Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). Journal of Clinical Oncology. 30: 180-180. DOI: 10.1200/Jco.2012.30.15_Suppl.E15108 |
0.377 |
|
| 2012 |
Bauer KS, Tavakkoli F, Bazzi M, Molchanova-Cook O, Chen W, Hussain A. Pharmacokinetics of samarium-153-EDTMP (153Sm) prior to and following zoledronic acid (ZA) in prostate cancer (PC) patients with bone metastases (BM). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13075 |
0.355 |
|
| 2012 |
Kwok Y, Saltos A, Boggs DH, Naslund M, Hussain A, Amin P. Long-term Follow-up of Combined Modality Therapy With Pelvic External Radiation Followed by Cs-131 Brachytherapy Boost in Men With High-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1069 |
0.463 |
|
| 2011 |
Onukwugha E, Mullins CD, Hsu VD, Seal B, Hussain A. Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology. 77: 1088-1095. PMID 21439617 DOI: 10.1016/J.Urology.2010.11.059 |
0.462 |
|
| 2011 |
DiBiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N, Kwok Y. Long-Term Results of a Prospective, Phase II Study of Long-Term Androgen Ablation, Pelvic Radiotherapy, Brachytherapy Boost, and Adjuvant Docetaxel in Patients With High-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 81: 732-736. PMID 21036486 DOI: 10.1016/J.Ijrobp.2010.06.042 |
0.483 |
|
| 2011 |
Suer S, Zhang B, Hussain A, Burger AM. Abstract 4366: The telomere targeting agent sodium metaarsenite can eradicate the side population of hormone resistant prostate cancer cells Cancer Research. 71: 4366-4366. DOI: 10.1158/1538-7445.Am2011-4366 |
0.461 |
|
| 2010 |
Mullins CD, Onukwugha E, Bikov K, Seal B, Hussain A. Health disparities in staging of SEER-Medicare prostate cancer patients in the United States. Urology. 76: 566-572. PMID 20163844 DOI: 10.1016/J.Urology.2009.10.061 |
0.518 |
|
| 2010 |
Davidoff AJ, Zuckerman IH, Pandya NB, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Edelman MJ. Development of a performance status prediction model for use in administrative data analyses. Journal of Clinical Oncology. 28: 6006-6006. DOI: 10.1200/Jco.2010.28.15_Suppl.6006 |
0.3 |
|
| 2010 |
Onukwugha E, Mullins C, Seal B, Hussain A. Pcn43 Initial Costs Of Treatment Among Stage Iv Prostate Cancer (Pca) Chemotherapy Patients In Seer-Medicare Value in Health. 13. DOI: 10.1016/S1098-3015(10)72132-X |
0.502 |
|
| 2010 |
Kwok Y, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Dawson N, Amin P, Hussain A. Prospective Trial of Escalating Doses of Paclitaxel, Concurrent Radiation and Androgen Deprivation in High-risk Prostate Cancer with or without Prior Prostatectomy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.839 |
0.477 |
|
| 2009 |
Wu Y, Kwok Y, Mirmiran A, Goloubeva O, Mannuel H, Dawson N, Amin P, Hussain A. Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5122. PMID 27964408 DOI: 10.1200/Jco.2009.27.15_Suppl.5122 |
0.433 |
|
| 2009 |
Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A. Androgen deprivation and stem cell markers in prostate cancers. International Journal of Clinical and Experimental Pathology. 3: 128-38. PMID 20126580 |
0.322 |
|
| 2009 |
Tang Y, Wang L, Goloubeva O, Khan MA, Lee DI, Hussain A. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. The Prostate. 69: 1763-1773. PMID 19691128 DOI: 10.1002/Pros.21026 |
0.452 |
|
| 2009 |
Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. Journal of Immunotherapy. 32: 655-666. PMID 19483644 DOI: 10.1097/Cji.0B013E3181A80E0D |
0.385 |
|
| 2009 |
Burger AM, Zhang B, Nolan P, Brucz B, Hussain A. Abstract A57: The telomere targeting agent sodium metaarsenite (KML001) exhibits activity in taxane‐resistant prostate cancer (PC) cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A57 |
0.381 |
|
| 2009 |
Onukwugha E, Mullins C, Seal B, Hussain A. Pcn97 Physician Referral Patterns Among Elderly Patients With Stage Iv Prostate Cancer (Pca): An Analysis Using Seermedicare Data Value in Health. 12. DOI: 10.1016/S1098-3015(10)73334-9 |
0.497 |
|
| 2009 |
Onukwugha E, Mullins C, Seal B, Hussain A. Pcn12 Timing Of Physician Visits And The Impact On Survival Among Seer-Medicare Patients With Stage Iv Prostate Cancer Value in Health. 12. DOI: 10.1016/S1098-3015(10)73249-6 |
0.487 |
|
| 2009 |
Onukwugha E, Mullins C, Seal B, Hussain A. Pmc36 The Population Impact Of Chemotherapy In Late-Stage Prostate Cancer: A Simulation Study Using Tax327 And Seer-Medicare Data Value in Health. 12. DOI: 10.1016/S1098-3015(10)73187-9 |
0.471 |
|
| 2008 |
Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clinical Cancer Research. 14: 2936-2943. PMID 18483360 DOI: 10.1158/1078-0432.Ccr-07-4925 |
0.427 |
|
| 2008 |
Tummala MK, Hussain A. Recent developments in germ cell tumors of the testes Current Opinion in Oncology. 20: 287-293. PMID 18391628 DOI: 10.1097/Cco.0B013E3282F8B064 |
0.301 |
|
| 2007 |
Lee DI, Sumbilla C, Lee M, Natesavelalar C, Klein MG, Ross DD, Inesi G, Hussain A. Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. Archives of Biochemistry and Biophysics. 464: 19-27. PMID 17475205 DOI: 10.1016/J.Abb.2007.03.040 |
0.339 |
|
| 2006 |
Mannuel HD, Hussain A. Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer. Clinical Genitourinary Cancer. 5: 43-9. PMID 16859578 DOI: 10.3816/CGC.2006.n.016 |
0.384 |
|
| 2006 |
O'Neill JP, Velalar CN, Lee DI, Zhang B, Nakanishi T, Tang Y, Selaru F, Ross D, Meltzer SJ, Hussain A. Thapsigargin resistance in human prostate cancer cells. Cancer. 107: 649-59. PMID 16770788 DOI: 10.1002/Cncr.22027 |
0.399 |
|
| 2006 |
Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 169-74. PMID 16397039 DOI: 10.1158/1078-0432.Ccr-05-1388 |
0.551 |
|
| 2006 |
Picus J, Halabi S, Small E, Hussain A, Philips G, Kaplan E, Vogelzang N. Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782 Journal of Clinical Oncology. 24: 4573-4573. DOI: 10.1200/Jco.2006.24.18_Suppl.4573 |
0.42 |
|
| 2005 |
Hussain A, Tang Y, Khan MA, Goloubeva O. Docetaxel (D) followed by castration (C) improves anti-tumor effects in human prostate cancer cell-bearing SCID mice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4638. PMID 27947014 DOI: 10.1200/Jco.2005.23.16_Suppl.4638 |
0.515 |
|
| 2005 |
Mannuel HD, Dawson N, Khan I, Feldman M, Boyle L, Besche M, Smoot J, Engstrom C, Monroe M, Hussain A. Initial results of ongoing phase I/II studies of weekly doxorubicin (Doxo)/docetaxel (Doce) in men with hormone refractory (HRPC) and hormone sensitive prostate cancer (HSPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4665. PMID 27946813 DOI: 10.1200/Jco.2005.23.16_Suppl.4665 |
0.449 |
|
| 2005 |
Smith MR, Kabbinavar F, Saad F, Hussain A, Hei YJ, Small E, Cook R, Higano C. Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4514. PMID 27946530 DOI: 10.1200/Jco.2005.23.16_Suppl.4514 |
0.534 |
|
| 2005 |
Mannuel HD, Hussain A. What constitutes high-risk locally advanced prostate cancer? Clinical Genitourinary Cancer. 4: 193-196. PMID 16425988 DOI: 10.3816/Cgc.2005.N.032 |
0.501 |
|
| 2005 |
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2918-25. PMID 15860850 DOI: 10.1200/Jco.2005.01.529 |
0.522 |
|
| 2005 |
Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, Guo C. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2789-96. PMID 15837994 DOI: 10.1200/Jco.2005.07.152 |
0.526 |
|
| 2005 |
DiBiase SJ, Dawson N, Kwok Y, Kataria R, Hussain A, Nagda S, Bangalore M, Amin P. Phase II Trial of External Radiotherapy, Brachytherapy, Androgen Deprivation and Docetaxel Chemotherapy for High-Risk, Localized Prostate Cancer International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.507 |
0.49 |
|
| 2004 |
Dibiase SJ, Dawson N, Naslund M, Hussain A, Kataria R, Bangalore M, Dhople A, Guo C, Amin P. Phase II study of combined external beam radiation therapy (EBRT), brachytherapy (PB), total androgen suppression (TAS), and adjuvant docetaxel (AD) in poor-risk, localized prostate cancer (PCa). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4764. PMID 28017046 DOI: 10.1200/Jco.2004.22.14_Suppl.4764 |
0.425 |
|
| 2004 |
Picus J, Halabi S, Small E, Hussain A, Philips G, Kaplan E, Vogelzang N. Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782 Journal of Clinical Oncology. 22: 4559-4559. DOI: 10.1200/Jco.2004.22.14_Suppl.4559 |
0.533 |
|
| 2003 |
DiBiase SJ, Dawson NA, Naslund MJ, Hussain A, Bangalore M, Dhople A, Guo C, Amin P, Jacobs S. Combined external beam radiation therapy (EBRT), brachytherapy (PB), total androgen suppression (T AS), and adjuvant docetaxel (AD) in poor-risk, localized prostate cancer (PCa) European Urology Supplements. 2: 17. DOI: 10.1016/S1569-9056(03)90396-4 |
0.459 |
|
| 2001 |
Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Seminars in Oncology. 28: 22-31. PMID 11685725 DOI: 10.1016/S0093-7754(01)90151-4 |
0.504 |
|
| 1990 |
Doyle LA, Borges M, Hussain A, Elias A, Tomiyasu T. An adherent subline of a unique small-cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule. Journal of Clinical Investigation. 86: 1848-1854. PMID 1701450 DOI: 10.1172/Jci114915 |
0.308 |
|
| Show low-probability matches. |